Pivotal T-cell engager readouts approach
Data on J&J’s Tecvayli and Pfizer’s Elrexfio in relapsed multiple myeloma are due soon.
Arvinas leader departs under a Pfizer-shaped cloud
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
Licensing analysis: big deals bolster biotech
PD-(L)1 x VEGF bispecifics prove a big draw.
Regeneron enters the T-cell engager arena
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
BeOne also needs B7-H4 biomarkers
The company’s BG-C9074 looks competitive, but there are questions about cutoffs and confirmed responses.
ASCO 2025 – vepdegestrant matches rival degraders
Any hopes of differentiation could come down to side effects.
ASCO 2025 preview – Kura looks similar to Syndax
Meanwhile, Pfizer reckons it's found the right dose for its KAT6.
Pfizer bets big on a bispecific
The company is paying $1.25bn for a PD-1 x VEGF project, the largest deal here yet.
